Aura Biosciences Announces Clinical Data at AAO 2019 Annual Meeting

Aura Biosciences Announces Clinical Data Presentations at the Upcoming American Academy of Ophthalmology 2019 Annual Meeting


CAMBRIDGE, Mass.– Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced multiple data presentations at the upcoming American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA. Aura’s lead clinical asset, AU-011, will also be highlighted in presentations at related medical meetings taking place in San Francisco around AAO 2019, including the Ophthalmology Innovation Summit taking place October 10, 2019, and the American Association of Ophthalmic Oncologists and Pathologists (AAOOP) 2019 Annual Meeting taking place October 13, 2019.

Two key presentations at the AAO meeting include study updates by key opinion leaders Dr. Jay S. Duker, Director New England Eye Center, Professor and Chair Tufts Medical Center and Dr. Amy C. Schefler, Weill Cornell Medical College and Retina Consultants of Houston, which will include updated clinical data from Aura’s ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma. An additional presentation will be given at AAOOP 2019 by Dr. Abdhish Bhavsar, Board Certified Ophthalmologist at The Retina Center and an investigator for Aura’s Phase 1b/2 clinical trial.

“There are no FDA approved therapies for the treatment of choroidal melanoma, the most common type of primary eye cancer,” said Cadmus Rich, MD, Chief Medical Officer of Aura Biosciences. “Patients are currently treated with radiotherapy and surgery which typically results in severe vision loss, along with many other significant adverse effects and comorbidities. If approved, AU-011 will be the first targeted therapy for the treatment of choroidal melanoma, with the potential to not only provide tumor control, but also preserve vision. We are excited to have these presentations on our AU-011 program and we look forward to sharing our novel technology, clinical data and an update on new delivery methods for AU-011 with the ophthalmology community at AAO and the accompanying events this year.”

The details for the AAO 2019 presentations are as follows:

Title: Aura Biosciences
Presenter: Jay S. Duker, MD, New England Eye Center, Tufts Medical Center
Session: SYM22 The Innovators Symposium
Date and time: Sunday, October 13, 2019 from 2:47 – 2:54 PM PT
Location: Moscone Center, Esplanade Room

Title: Virus-Like Particles for Uveal Melanoma
Presenter: Amy C. Schefler, MD, Weill Cornell Medical College/Retina Consultants of Houston
Session: SYM50 Delivery of Therapeutics to the Posterior Ocular Segment
Date and time: Tuesday, October 15, 2019 from 9:35 – 9:45 AM PT
Location: Moscone Center, West 2002

Additional presentations taking place at other events in San Francisco around AAO 2019 include:

Event: Ophthalmology Innovation Summit (OIS) @ AAO
Title: Update on Aura Biosciences
Presenter: Elisabet de los Pinos, PhD, Chief Executive Officer of Aura Biosciences
Session: Innovation Showcase 1
Date and time: Thursday, October 10, 2019 from 8:40-8:47 AM PT
Location: Hilton San Francisco Union Square, 333 O’Farrell Street

Event: American Association of Ophthalmic Oncologists and Pathologists (AAOOP) 2019 Annual Meeting
Title: Study Update of an Ongoing Phase 1b/2 Open-label Clinical Trial of AU-011 for the Treatment of Small to Medium Choroidal Melanoma
Presenter: Abdhish Bhavsar, MD, The Retina Center
Date and time: Sunday, October 13, 2019
Location: Grand Hyatt San Francisco, 345 Stockton Street

About Aura Biosciences

Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells. Its lead program, AU-011 for the treatment of primary choroidal melanoma, is being developed under a CRADA with the National Cancer Institute (NCI), part of the National Institutes of Health. For more information, visit or follow us on Twitter.